Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_2
6
100%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

completed350%
terminated350%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

NCT02955888
terminatedphase_2

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

NCT03081598
terminatedphase_2

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

NCT03184584
completedphase_2

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT02538536
completedphase_2

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

NCT02739217
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02955888Phase 2

Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

Terminated
NCT03081598Phase 2

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

Terminated
NCT03184584Phase 2

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Terminated
NCT02538536Phase 2

A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed
NCT02739217Phase 2

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

Completed
NCT02562573Phase 2

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6